RxDoctor Payments Data

Dominick Galluzzo, MD

Internal Medicine · Meadowbrook, PANPI 1770554966

Payments from drug & device makers

$2,294in general payments, 2019–2025

Across 128 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$546
  • AbbVie$440
  • Pfizer$323
  • Astellas Pharma US Inc$232
  • Lilly USA, LLC$134
  • GSK$96
  • plus $523 from 15 others

What the payments were for

  • Food & beverage$2,294100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,294 in reported general payments places this provider in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$116,011
Medicare patients
452
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin115$133,817
EliquisApixaban127$125,029
OzempicSemaglutide73$84,385
TrulicityDulaglutide30$40,460
XifaxanRifaximin14$28,816
XareltoRivaroxaban26$27,557
AbrysvoRsv Vacc, Pref A And Pref B/Pf70$22,165
JanumetSitagliptin Phos/Metformin Hcl20$21,564
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$15,885
InvokanaCanagliflozin16$13,874
Spiriva HandihalerTiotropium Bromide16$13,758
Atorvastatin Calcium828$11,831
BrilintaTicagrelor12$8,947
LinzessLinaclotide11$8,580
MyrbetriqMirabegron15$6,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$323$147,194197 claims
Boehringer IngelheimJardiance$66$133,817115 claims
Novo NordiskOzempic$546$84,38573 claims
Johnson & JohnsonXarelto, Invokana$42$41,43142 claims
Lilly USA, LLCTrulicity$134$40,46030 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$16$28,81614 claims
MerckJanumet$35$21,56420 claims
GSKTrelegy Ellipta$96$15,88526 claims
AbbVieLinzess, Synthroid$440$11,96249 claims
Astellas Pharma US IncMyrbetriq$232$6,45715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Meadowbrook

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →